Investors Can't Peg ProNAi For Failed Cancer Drug
Pharmaceutical maker ProNAi Therapeutics Inc. and two of its executives shed a proposed securities class action on Tuesday when a New York federal judge found most of the company's statements about...To view the full article, register now.
Already a subscriber? Click here to view full article